Индоксил сульфат при хронической болезни почек
Аннотация
В обзоре приведены литературные данные о механизмах токсического действия индоксил сульфата при дисфункции почек.
Об авторах
Б. Г. Лукичёв
Первый Санкт-Петербургский государственный медицинский университет им акад. И.П. Павлова
Россия
Россия
О. Ю. Подгаецкая
ООО Центр семейной медицины «Моника»
Россия
Россия
А. В. Карунная
Первый Санкт-Петербургский государственный медицинский университет им акад. И.П. Павлова
Россия
Россия
А. Ш. Румянцев
Первый Санкт-Петербургский государственный медицинский университет им акад. И.П. Павлова
Россия
Россия
Список литературы
1. Vanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63 (5): 1934-1943
2. Bergstrom J., Furst P. Uremic toxins. Kidney Int 1978; 8 (Suppl. 1): 9-12
3. Rutkowski P. Kliniczne i metaboliczne nastêpstwa zatrucia mocznicowego. Przegl Lek 2006; 63 (4): 209-217
4. Vanholder R., De Smet R., Lameire NH. Redesigning the map of uremic toxins. Contrib Nephrol 2001; 133: 42-70
5. Chiang C.K., Tanaka T., Nangaku M. Dysregulated oxygen metabolism of the kidney by uremic toxins: review. J Ren Nutr 2012; 22(1): 77-80
6. Синюхин В.Н., Стецюк Е.А., Арзуманов С.В. Экспериментальная и клиническая урология 2013; 1: 30-35
7. Cohen G., Glorieux G., Thornalley P. et al. Review on uraemic toxins III. Recommendation for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. NDT 2007; 22: 3381-3390
8. Сивков А.В., Синюхин В.Н., Бебешко Е.В. Уремический токсин паракрезол у больных с терминальной стадией ХПН. Экспериментальная и клиническая урология 2012; № 1: 68-71
9. Vanholder R., Schepers E., Pletinck A. et al. An update on protein-bound uremic retention solutes. J Ren Nutr 2012; 22 (1): 90-94
10. Wengle B., Hellström K. Volatile phenols in serum of uraemic patients. Clin Sci 1972; 43: 493-498
11. Niwa T. Phenol and p-cresol accomuiated in uremic serum measured by HPLC with fluorescence detection. Clin Chem 1993; 39: 108-111
12. Niwa T., Ise M., Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994; 14(3): 207-212
13. Niwa T., Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96-104
14. Hanly P.J., Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344: 102-107
15. Kochanek K.D., Xu J., Murphy S.L., Minino A.M., Kung H.S. Deaths: preliminary Data for 2009. Nat Vital Stat Rep 2011; 4: 59
16. Foley R.N., Murray A.M., Li S., Herzog C.A., McBean A.M., Eggers P.W., Collins A.J. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495
17. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология. 2005; 9(3): 7-15
18. Шутов А.М., Серов В.А. Кардиоренальный и ренокардиальный синдромы. Нефрология 2009; 13(4): 59-63
19. Bammens B., Evenepoel P., Verbeke K. et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relative with uremic symptoms. Kidney Int 2003; 64: 2238-2243
20. Bammens B., Evenepoel P., Keuleers H. et al. Free serum concentration of the protein-bound retention solute p-cresol predicts mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087
21. De Smet R., Kaer J. van, Vlem B. et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chemistry 2003; 49: 470-478
22. Liabeuf S., Drüeke T.B., Massy Z.A. Protein-Bound Uremic Toxins: New Insight from Clinical Studies. Toxins 2011; 3: 911-919
23. Sirich T.L., Luo F.J., Plummer N.S., Hostetter T.H., Meyer T.W. Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 2012; 27(4): 1574-1579
24. Bammens B., Evenepoel P., Keuleers H., Verbeke K., Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087
25. Enomoto A., Takeda M., Tojo A. et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002; 13: 1711-1720
26. Cheng-Jui Lin, Chih-Kuang Chuang, Hsuan-Liang Liu et al. The serum levels of P-cresol and Indoxyl sulfate in different hemodialysis vintage. J Clin Medicine and Research 2011; 3(8): 114-119
27. Meert N., Beerenhout C., Schepers E., Glorieux G., Kooman J.,Vanholder R. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009; 22 (3): 352-357
28. Fagugli R.M., De Smet R., Buoncristiani U., Lameire N., Vanholder R. Behavior of nonprotein-bound and proteinbound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002; 40 (2): 339-347
29. Martinez A., Recht N., Hostetter T., Meyer T. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3437
30. De Smet R., David F., Sandra P., Van Kaer J. et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin him Acta 1998; 278: 1-21
31. De Loor H., Bammens B., Evenepoel P. et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51(8): 1535-1538
32. Niwa T. Update of uremic toxin research by mass spectrometry. Mass Spectrom 2011; 30(3): 510-521
33. Niwa T., Miyazaki T., Tsukushi S. et al. Accumulation of indoxil-beta-D-glucuronide in uremic serum: supression of its production by oral sorbent and efficient removal by hemodialysis. Nephron 1996; 74: 72-78
34. Lin C.J., Wu C.J., Pan C.F. et al. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 3693-3700
35. Meijers B.K., Bammens B., de Moor et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-1180
36. Niwa T., Nomura T., Sugiyama S., Miyazaki T., Tsukushi S., Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997; 62 (Suppl 1) S23-S28
37. Sanaka T., Sugino N., Teraoka S., Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12: 97-103
38. Fujii H., Nishijima F., Goto S. et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009; 24: 2089-2095
39. Lin C.J., Chen H.H., Pan C.F. et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011; 25(3): 191-197
40. Curtius H.C., Mettler M., Ettlinger L. Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 1976; 126: 569-580
41. Vanholder R., Meert N., Schepers E. et al. Review on uraemic solutes II-Variability in reported concentrations: causes and consequences. NDT 2007; 22: 3115-3121
42. Burchell B., Coughtrie M.W. Genetic and environmental factors associated with variation of human xenobiotic glucuroni-dation and sulfation. Environ Health Perspect 1997; 105 (Suppl. 4): 739-747
43. Vanholder R., Bammens B., de Loor H. et al. The unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 2011; 26(5): 1464-1467
44. Vanholder R., van Laecke S., Glorieux G. What is new in uremic toxicity? Pediatr Nephrol 2008; 23(8): 1211-1221
45. Meijers B.K., Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011; 26(3): 759-761
46. de Carvalho J.T. Jr, Dalboni M.A., Watanabe R. et al. Effects of spermidine and p-cresol on polymorphonuclear cell apoptosis and function. Artif Organs 2011; 35(2): 27-32
47. Галишон П., Гертиг А. Эпителиально-мезенхимальная трансформация как биомаркер почечного фиброза: готовы ли мы применить теоретические знания на практике? Нефрология 2013; 17 (4): 9-16
48. Miyazaki T., Ise M., Hirata M. et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int Suppl 1997; 63: S211-S214
49. Adijiang A., Shimizu H., Higuchi Y. et al. Indoxyl sulfate reduces klotho expression and promotes senescence in the kidneys of hypertensive rats. J Ren Nutr 2011; 21: 105-109
50. Namba S., Okuda Y., Morimoto A. et al. A serum indoxil sulfate is a useful predictor of chronic kidney disease. Rinsho Byori 2010; 58(5): 448-453
51. Nii-Kono T., Iwasaki Y., Uchida M. et al. Indoxil sulfate induces skeletal resistance to parathyreoid hormone in cultured osteoblastic cell. Kidney Int 2007: April,71(8); 738-743
52. Chiang C.K., Tanaka T., Inagi R. et al. Indoxil sulfate, a representative uremic toxin suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 2011; 91(11): 1564-1571
53. Shimizu H., Bolati D., Adijiang A. et al. Indoxil sulfate down-regulates renal expression of Klotho troungh production of ROS and activation of nuclear factor-kB. Am J Nephrol 2011: 33(4); 319-324
54. Kawakami T., Inagi R., Wada T. et al. Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol 2010; 299(3): F568-F576
55. Shimizu H., Bolati D., Adijiang A. et al. Senescence and dysfunction of proximal tubular cells are associated with activated p 53 expression by indoxil sulfate. J Cell Physiol 2010; 299(5): 1110-1117
56. Oda T., Yung Y., Kim H. et al. PAI-1 deficiency attenuates the fibrigenic response to uretral obstruction. Kidney Int 2001; 60: 587-596
57. Wooin Lee, Richard B. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; V 44: 137-166
58. Richard B. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; V 44: 137-166
59. Taki K., Nakamura S., Miglinas M., Enomoto A., Niwa T. Accumulation of indoxyl sulfate in OAT1/3-positive tubular cells in kidneys of patients with chronic renal failure. J Ren Nutr 2006 Jul; 16(3): 199-203
60. Hosoya K., Tachikawa M. Role organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins. Clin Exper Nephrol 2011; 15(4): 478-485
61. Бердникова Н.Г. Особенности фармакокинетики лекарственных средств при заболеваниях почек и у больных на гемодиализе. В: Кукес В.Г., ред. Клиническая фармакокинетика: теоретические, прикладные и аналитические аспекты. ГЭОТАР-Медиа, М., 2009; 186-197
62. Niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 2010; 72: 1 - 11
63. W u I.W., Hsu K.H., Lee C.C. et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011; 26(3): 938-947
64. Yu M., Kim Y.J., Kang D.H. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011; 6 (5): 30-39
65. Miyamoto Y., Watanabe H., Otagiri M., Maruyama T. New insight into the redox properties of uremic solute indoxyl sulfate as a pro- and anti-oxidant. Ther Apher Dial 2011; 15 (2): 129-131
66. Motojima M., Nishuima F., Ikoma M. et al. Role for ”uremic toxin” in progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 461-46
67. Niwa T., Miyazaki T., Hashimoto N. et al. Suppressed serum and urine levels of indoxil sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 1992; 12: 201-206
68. Rottenbourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int 1993; 43 (Suppl. 40): S106-S110
69. Gelasco A.K., Raymond J.R. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 2006 Jun; 290(6): F1551-8
70. Motojima M., Hosokawa A., Yamato H. et al. Uraemic toxins induced proximal tubular injury via organic anion transporter 1-me-diated uptake. Br J Pharmacol 2002; 135: 555-563
71. Motojima M., Hosokawa A., Yamamoto H. et al. Uremic toxins of organic anions upregulate PAI-1 expression by induction of NF-kB and free radicalsin proximal tubular cells. Kidney Int 2003; 63 (6): 1671-1680
72. Кузьмин О.Б. Механизмы развития и прогрессирования нефропатии у больных сердечной недостаточностью с хроническим кардиоренальным синдромом. Нефрология 2011; 15, 2: 20-29
73. Niwa T. Role of indoxil sulfate in the progression of chronic kidneydisease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial 2011; 15(2); 120-124
74. Barreto F. et al. Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. Clin J. Of the American Society of Nephrology 2009; 4(10): 1551-1558
75. Fuji H., Nakai K., Fukagawa M. Role of oxidative stress and indoxil sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial 2011; 15(20): 125-128
76. Dou L., Bertrand E., Cerini C. et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451
77. Dou L., Jourde-Chiche N., Faure V. et al. The uremic solute indoxil sulfate induces oxidative stress in endothelial cells. J Thromb Heamost 2007; 5(6); 1302-1308
78. Miyamoto Y., Watanabe H., Otagiri M., Maruyama T. New Insinght into the redox properties of uremic solute indoxil sulfate as a pro and anti-oxidant. Ther Apher Dial 2011; 15(2); 129-131
79. Lekawanvijit S., Adrahtas A., Kelly D.J., Kompa A.R. et al. Does indoxil sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31(14): 1771-1779
80. Schepers E., Meert N., Glorieux G. et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596
81. Meijers B.K., Claes K., Bammens B. et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182-1189
82. Taki K., Tsuruta Y., Niwa T. Indoxil Sulfate and atherosclerotic Risk Factors in Hemodialysis Patients. Nephrology 2007; 27(1): 30 - 35
83. Owada S., Goto S., Bannai K., Hayashi H., Nishijima F., Niwa T. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol 2008; 28(3): 446-54
84. Adijiag A., Goto S., Uramoto S., Nishijima F., Niwa T. Indoxil sulfate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008; 23(6); 1892-1901
85. Yamamoto H., Tsuruoka S., Ioka T. et al. Indoxil sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006; 69: 1780-1785
86. Nii-Kono T., Iwasaki Y., Uchida M., Fujieda A., Hosokawa A., Motojima M.,Yamato H., Kurokawa K., Fukagawa M. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007; 71: 738-743
87. Iwasaki Y., Yamato H., Nii-Kono T., Fujieda A., Uchida M., Hosokawa A., Motojima M., Fukagawa M. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006; 21: 2768-2774
Рецензия
Для цитирования:
Лукичёв Б.Г., Подгаецкая О.Ю., Карунная А.В., Румянцев А.Ш. Индоксил сульфат при хронической болезни почек. Нефрология. 2014;18(1):25-32. https://doi.org/10.24884/1561-6274-2014-18-1-20-24
For citation:
Lukichev B.G., ., Karunnaya A.V., Rumyantsev A.S. Indoxyl sulphate at chronic kidney disease. Nephrology (Saint-Petersburg). 2014;18(1):25-32. (In Russ.) https://doi.org/10.24884/1561-6274-2014-18-1-20-24
Просмотров: 345
Послать статью по эл. почте 